VIDAC PHARMA HOLDING PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.196 EUR | -4.85% |
|
-2.00% | -63.70% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
More news
| 1 day | -4.85% | ||
| 1 week | -2.00% | ||
| Current month | -2.00% | ||
| 1 month | -25.76% | ||
| 3 months | -75.50% | ||
| 6 months | -64.36% | ||
| Current year | -63.70% |
1 week
0.20
0.21
1 month
0.190.23
Current year
0.191.22
1 year
0.191.63
3 years
0.191.63
5 years
0.191.63
10 years
0.191.63
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company. It is focused on discovering and developing medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. It develops anti-cancer drugs by modifying the hyper glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize the tumor microenvironment and selectively provoke their programmed death without affecting surrounding normal tissue. Its pipeline includes VDA-1102 Ointment, VDA-1102 IV and VDA-1275. VDA-1102 ointment is a drug that selectively targets malignant cutaneous cells with minimal effects on surrounding healthy skin. VDA-1102 IV is an anti-neoplastic agent that utilizes a mechanism of action involving selective modulation of VDAC/HK2. VDA-1275 is a potent small molecule new chemical entity (NCE) with a mechanism of action that selectively modulates VDAC/HK2 interaction.
| 1st Jan change | Capi. | |
|---|---|---|
| -63.70% | 10.87M | |
| +2.97% | 108B | |
| +10.21% | 105B | |
| +1.57% | 23.46B | |
| -12.77% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.50% | 17.19B | |
| +6.00% | 13.99B | |
| +37.20% | 12.53B |
- Stock Market
- Equities
- T9G Stock